ACHC Acadia Healthcare Company, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ACHC Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Medical Care Facilities
Current Price
Live
$16.77
Analyst Target
$19.07
+13.7%
Upside
52W High
$42.85
52W Low
$11.43
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 14, 2026
Market cap
$1.52B
P/E
13.75
ROE
3.7%
Profit margin
3.3%
Debt/Equity
0.74
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ACHC's Piotroski F-Score of 4/9 indicates weak financial health, signaling deterioration in operational efficiency and profitability trends. The company trades at a deeply discounted valuation (P/E: 13.75, Price/Book: 0.49) relative to its sector, but this is overshadowed by a 45.9% YoY earnings collapse and negative growth momentum. While the Graham Number ($30.78) suggests undervaluation, the intrinsic value estimate ($8.54) reflects weak growth prospects and deteriorating fundamentals. The absence of an Altman Z-Score raises concern about default risk, especially given a Debt/Equity ratio of 0.74 and declining profitability. Despite a recent analyst 'buy' consensus, technical and cash flow data remain weak.
Key Strengths
Trading at a significant discount to Graham Number ($30.78) and intrinsic value ($8.54)
Strong gross margin (41.78%) and operating margin (14.04%) indicate pricing power and cost control
Consistent earnings beat rate (3/4 in last 4 quarters) and positive average surprise (+12.85%) suggest earnings quality
Low P/E (13.75) and Price/Book (0.49) suggest potential value opportunity if fundamentals stabilize
Stable current and quick ratios (1.44 and 1.20) indicate short-term liquidity resilience
Key Risks
Piotroski F-Score of 4/9 indicates weak financial health and declining operational efficiency
45.9% YoY earnings decline and -46.8% Q/Q earnings growth signal severe deterioration in profitability
No Altman Z-Score available with a Debt/Equity of 0.74—raises potential bankruptcy risk if leverage increases
Negative revenue and earnings growth trends persist despite past strength; 5-year return down 67.8%
Zero insider buying in 6 months and neutral sentiment suggest lack of confidence from management
AI Fair Value Estimate
Based on comprehensive analysis
$8.54
-49.1% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
42
Moderate
78
30
65
35
0
AI Verdict
weak
Key drivers: Deteriorating earnings growth (-45.9% YoY), Low Piotroski F-Score (4/9), Negative technical trend (0/100), High sector-wide volatility and poor peer performance, Lack of dividend and weak cash flow indicators
Confidence
85%
Value
78/100
Ref P/E, PEG, Graham Number
Positives
- P/E of 13.75 is below sector average (197.64)
- Price/Book of 0.49 indicates deep discount to book value
- Graham Number ($30.78) is significantly above current price ($16.77)
- Intrinsic value estimate ($8.54) suggests undervaluation if growth recovers
Watchpoints
- PEG ratio unavailable, limiting growth-adjusted valuation
- Current price is above intrinsic value estimate ($8.54), suggesting overvaluation relative to growth
- High discount may reflect fundamental deterioration rather than opportunity
Future
30/100
Ref Growth rates
Positives
- Forward P/E of 9.63 suggests market expects earnings recovery
- Recent earnings surprises (avg +12.85%) indicate potential upside if trends reverse
Watchpoints
- Revenue growth: 4.40% YoY (low)
- Earnings growth: -45.90% YoY (severe decline)
- Q/Q earnings growth: -46.80% (accelerating decline)
- No visible growth catalysts in financials or operations
Past
65/100
Ref Historical trends
Positives
- Consistent earnings beats in 3 of last 4 quarters
- Historical track record of positive surprises (e.g., +108.6% in 2022)
- Stable margins over time (gross: 41.78%, operating: 14.04%)
Watchpoints
- Earnings have declined sharply in recent quarters
- 5-year return: -67.8%, 3-year: -79.3%—long-term underperformance
- Recent Q/Q EPS growth: -13.3%, indicating worsening trend
Health
35/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio (1.44) and quick ratio (1.20) indicate adequate liquidity
- Debt/Equity of 0.74 is moderate for healthcare sector
Watchpoints
- Piotroski F-Score of 4/9 indicates weak financial health and declining operational efficiency
- No Altman Z-Score available—raises default risk concerns
- ROE (3.69%) and ROA (4.52%) are low despite margin strength
- Negative earnings growth undermines capital efficiency
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength: 0/100
- No history of dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$16.77
Analyst Target
$19.07
Upside/Downside
+13.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACHC and closest competitors.
Updated 2026-02-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACHC
Acadia Healthcare Company, Inc.
Primary
|
-67.8% | -79.3% | -59.8% | -20.1% | +43.0% | +25.4% |
|
AXGN
Axogen, Inc.
Peer
|
+76.4% | +203.1% | +75.6% | +145.6% | +0.6% | +5.8% |
|
ATAI
AtaiBeckley Inc.
Peer
|
-78.7% | +117.3% | +174.8% | +16.2% | -0.9% | +14.0% |
|
AGIO
Agios Pharmaceuticals, Inc.
Peer
|
-52.5% | -14.2% | -22.9% | -25.8% | -7.0% | -3.3% |
|
AHCO
AdaptHealth Corp.
Peer
|
-70.2% | -48.4% | +10.2% | +15.9% | +1.4% | +6.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
13.75
Forward P/E
9.63
PEG Ratio
N/A
P/B Ratio
0.49
P/S Ratio
0.46
EV/Revenue
1.24
EV/EBITDA
6.46
Market Cap
$1.52B
Profitability
Profit margins and return metrics
Profit Margin
3.29%
Operating Margin
14.04%
Gross Margin
41.78%
ROE
3.69%
ROA
4.52%
Growth
Revenue and earnings growth rates
Revenue Growth
+4.4%
Earnings Growth
-45.9%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
-46.8%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.74
Moderate
Current Ratio
1.44
Good
Quick Ratio
1.2
Good
Cash/Share
$1.29
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-25
$N/A
2025-11-05
$0.72
+9.2% surprise
2025-08-05
$0.83
+17.4% surprise
2025-05-12
$0.4
+12.0% surprise
Healthcare Sector Comparison
Comparing ACHC against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
P/E Ratio
13.75
This Stock
vs
197.69
Sector Avg
-93.0%
(Discount)
Return on Equity (ROE)
3.69%
This Stock
vs
-56.84%
Sector Avg
-106.5%
(Below Avg)
Profit Margin
3.29%
This Stock
vs
-20.8%
Sector Avg
-115.8%
(Weaker)
Debt to Equity
0.74
This Stock
vs
2.68
Sector Avg
-72.2%
(Less Debt)
Revenue Growth
4.4%
This Stock
vs
61.93%
Sector Avg
-92.9%
(Slower)
Current Ratio
1.44
This Stock
vs
3.47
Sector Avg
-58.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACHC
Acadia Healthcare Company, Inc.
|
BEARISH | $1.52B | 13.75 | 3.7% | 3.3% | $16.77 | |
|
AXGN
Axogen, Inc.
|
NEUTRAL | $1.51B | - | -1.9% | -1.0% | $32.83 | |
|
ATAI
AtaiBeckley Inc.
|
BEARISH | $1.51B | - | -100.8% | -% | $4.15 | |
|
AGIO
Agios Pharmaceuticals, Inc.
|
BEARISH | $1.55B | - | -27.6% | -% | $26.53 | |
|
AHCO
AdaptHealth Corp.
|
BEARISH | $1.44B | 19.02 | 5.5% | 2.5% | $10.65 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-10-27 | YOUNG TODD S | Chief Financial Officer | Stock Award | 48,445 | - |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
14 analysts
Jefferies
2026-01-22
Buy
Hold
TD Cowen
2026-01-16
Buy
Buy
RBC Capital
2026-01-14
Outperform
Outperform
Mizuho
2025-12-18
Neutral
Neutral
Barclays
2025-12-04
Equal-Weight
Equal-Weight
RBC Capital
2025-12-03
Outperform
Outperform
Cantor Fitzgerald
2025-12-03
Neutral
Neutral
Keybanc
2025-12-03
Overweight
Overweight
UBS
2025-12-03
Buy
Buy
Deutsche Bank
2025-12-03
Buy
Buy
Past News Coverage
Recent headlines mentioning ACHC from our newsroom.
Newest → oldest
No matching news yet.